Patient registries, frequently referred to as outcome registries, are 'organized systems' that use observational study methods to collect uniform data. Registries are used to evaluate specified outcomes for a population defined by a particular disease, condition or exposure that serves one or more predetermined scientific, clinical or policy purposes. Outcome registries were established very early in the development of hematopoietic SCT (HSCT). Currently, myriads of national and international HSCT registries collect information about HSCT activities and outcomes. These registries have contributed significantly to determining trends, patterns, treatment practices and outcomes. There are many different HSCT registries, each with different aims and goals; some are led by professional organizations, others by government authorities, health care providers or third parties. Some registries simply assess activity and others study outcomes. These registries are complementary and are gradually developing interoperability with each other to expand future collaborative research activities. A key development in the last few years was the incorporation of recommendations into the World Health Organization guiding principles on cell, tissue and organ transplantation. The data collection and analysis should be an integral part of therapy and an obligation rather than a choice for transplant programs. This article examines challenges in ensuring data quality and functions of outcome registries, using HSCT registries as an example. It applies to all HSCT-related data, but is predominantly focused on HSCT registries of professional organizations.
INTRODUCTION
There is a growing recognition of the value of observational data as a research tool in assessing utilization and patterns of medical care as well as facilitating outcome analysis to fill evidence gaps regarding safety and effectiveness. Patient registries, typically referred to as outcome registries, are the 'organized systems' that utilize observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a particular disease, condition or exposure. This outcome data and analysis can in turn, serves as the basis for future scientific and clinical trials or policy purposes. 1 Registries are classified according to how their populations are defined and their purpose. Populations may be defined by disease or conditions, exposures such as treatments, procedures or adverse events or groups defined by boundaries such as geography, socio-economic status and other arbitrary measures. The most common purposes of registries are to describe the natural history of disease or exposure, determine effectiveness, measure safety and toxicity and assess quality in a systematic approach.
Outcome registries were established very early in the development of hematopoietic SCT (HSCT), a treatment of choice for myriads of hematological malignancies and other life-threatening diseases. As outcome registries are observational, the basic source document is usually the patient's medical record from which pertinent information is abstracted for use in the registry. HSCT registries provide a tool for understanding the trends and patterns of HSCT in a defined population. They can serve as a local, national, regional or international resource or a combination, thereof. These registries are a major source of clinical information and can have an important role in monitoring and influencing HSCT activities and guidelines. They facilitate research into HSCT outcomes by addressing questions difficult to answer by clinical trials 2 or complementing clinical trial findings. 3 Registries also form the basis for prevention/intervention program development, delivery and effectiveness. They can help in designing the optimal schema for prospective and retrospective studies and for comparative analyses of diverse HSCT strategies or for HSCT versus non-HSCT therapies. If data collection is sufficiently comprehensive, outcome findings from patient registries can be widely generalizable.
By introducing data feedback and reporting loops, registries can be made synergistic with continuous quality improvement processes and can lead to patient care optimization with minimization of complications. Registries provide insight into the patient population, demographics, changing patterns of disease interventions and rates of complications. Providing baseline data, trend analysis and outcome measurements is the primary objective of these registries. These can be a foundation for improving the overall health and quality of life of HSCT patients. Outcome measurement evaluates the patient's improvement and the treatment's effectiveness.
The value of HSCT registries is enhanced when they are based on established international ethical and quality standards for the design, collection, analysis, reporting, monitoring and auditing of outcome data for donors and recipients. Easy accessibility of data from such registries to the participating physicians and safeguards for credible and accurate data are essential ingredients of a quality registry. The registry should also provide assurance for the integrity and confidentiality of the data.
Regional HSCT registries can promote HSCT in the region, identify loco-regional trends and practices, standards and interventions and may also be helpful in benchmarking HSCT outcomes. A study from the United Kingdom and Ireland recently compared their data with data in the large multinational outcome registry maintained by the European Group for Blood and Marrow Transplantation (EBMT), and demonstrated the potential for using national registries to benchmark transplant outcome using the EBMT registry as reference. 4 The Center for International Blood and Marrow Transplantation (CIBMTR) annually assesses 1-year survival after allogeneic HSCTs in each US transplant center and makes these results available to participating transplant programs, and the public.
5, 6 Globalization of patient and donor registration for HSCT is a realistic goal and can contribute to the improvement of patient care, outcomes and donor safety. 7, 8 Registry data have provided important insights into international differences in indications for HSCT, and access to HSCT. 9, 10 Data from outcome registries may be useful to evaluate differences in outcomes across regional or international settings to identify modifiable practices and inform program improvement.
Observational studies, databases and registries offer many advantages and valuable information (Table 1) , if designed, maintained and analyzed properly. The availability of detailed clinical information from registries, combined with powerful statistical analysis, provides timely and accurate information on the safety and effectiveness of HSCT in hematological malignancies and large number of inherited and acquired hematologic disorders.
Transplant registries face a myriad of challenges ( Table 2 ) that are summarized below in terms of trained personnel, regulations, data collection, data standards, communication, quality management, data utilization and publications.
Qualified personnel Qualified and adequately trained personnel with HSCT background and skills, operating as a functional team to manage registries are essential to their value. Developing and maintaining these skill sets can be a continuous challenge. Expertise that may be critical to the operation of the registry include: subject matter experts with clinical and scientific expertise; project management; experts in biostatistics and epidemiology; data architects, database administrators and programmers and security experts; personnel experienced with human subjects protection privacy regulations and expertise in quality assurance procedures. Understanding the basic concepts of HSCT by all personnel, regardless of their role in the registry, allows tailoring of the registry to the particular uniqueness of the therapeutic modality and substantially increase their value.
Working collaboratively, these groups of experts can effectively manage the registry activities from data acquisition through dissemination of data, reports and publications. They must marshal resources to effectively administer the registry, and skillfully allocate those resources to optimize the balance between data collection, burden upon those providing data, and utilization of data for reports and publications of highest impact for the field.
Regulations-managing ethical, privacy and legal considerations Development and maintenance of outcome registries requires particular attention to human subjects' protection, privacy considerations and legal considerations in the collection, ownership and exchange of data for registry purposes, including public health and research. An appropriate security infrastructure is essential to protect these interests. The framework for these considerations is made more challenging when the operation of the registry involves international sharing. The bylaws, data transfer agreements, accreditation for standardization by the Joint Accreditation Committee of the International Society of Cellular Therapy Europe and the EBMT/Foundation for the Accreditation of Cellular Therapy and others are pivotal in streamlining regulatory trepidations. However, wide ranging human subject protection regulations in different countries, wide variations in ethical committees' composition and deliberations, multifarious consent issues and lack of a Central Institution Review Board all pose challenges, particularly for international registries.
Human subjects' protection must be addressed from an ethical and legal perspective for any outcome registry. However, because outcome registries are observational in nature, they are often considered 'low-risk' with regard to potential for harm to human subjects. Consent for use of data for research obtained from research subjects by outcome registries, must be addressed by the registry, however, registry functions for public health or government program purposes may not require specific consent for research.
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Safeguarding patients' privacy and data confidentiality are of utmost importance. Privacy concerns with regard to identifiable patient information can be addressed by registries by collection of de-identified data and collection of identifiable data for 'internal use' with linked identifiers. The legal framework to collect identifiable health information varies by country and purpose of the registry. Registry data collected in the context of a public health reporting obligation, such as the outcome registry requirements of the US CW Bill Young Cell Transplantation Program, are subject to different privacy considerations as a public health authority.
11 Table 1 . Strengths of HSCT registry-based research
• If comprehensive, excellent source of demographic and activity data-dynamic measure of patterns of care.
• Useful for planning intervention trials-hypothesis generation, calculating effect size and potential recruitment.
• 'Real world' therapeutic effectiveness and safety data (as opposed to efficacy)-compare disease management by program, region and country.
• Heterogeneity of standard practice across participating sites facilitates research into 'best practices' .
• Heterogeneity among study subjects.
• Detection of rare consequences is satisfied by large numbers of patients followed for long periods of time-a unique advantage.
• Low risk to participating subjects (observational rather than interventional) can promote broad participation.
• Flexibility: serves as a platform for extending observation or intervention to particular groups of subjects-sub-studies.
• Relatively low cost to develop and maintain on a per-patient basis.
• Useful as a comparative arm in comparative effectiveness research.
• Provide meaningful data for decision-making where a clinical trial is not feasible or practical.
• Estimates of impact of treatment are more realistic.
In HSCT, most outcome registries have chosen to obtain identifiable information with linked identifiers to expand the opportunity to connect the registry data to other important data sources. For instance, approximately half of the HSCT performed annually around the world use an allogeneic donor acquired through a donor registry or cord blood bank. As many donor registries and cord blood banks have regulatory obligations to report on outcomes of the products used for these transplants, the ability to connect patient outcomes with the donor product at the level of a donor or bank 'registry' is of high importance, and provides justification for collection of identifiable information. Between 25 and 30% of all allogeneic HSCT involve recipients and donors from different countries, the challenges of connecting these data while respecting the boundaries of international regulations are substantial, but represent an important opportunity for international HSCT registries. In HSCT, projects coordinated by the Worldwide Marrow Donor Association seek to overcome these challenges.
Several outcome registries collect international recipient outcome data, and collaborate to share the data to expand study size and evaluate regional differences. Use of limited identifiable information is important to avoid inclusion of overlapping patients from different registries in the analyses. Collection of limited identifiable information allows the outcome registry data to be linked to other important sources of data, such as disease incidence data, mortality databases and payer databases to leverage the research and quality improvement uses of HSCT data. Research applications of identifiable information often require authorization from the participating subject, which is usually collected at the time of consent for research.
The use of unique patient identifiers can be confusing and may lead to duplication. The major international registries including Center for International Blood and Marrow Transplantation, EBMT and the Asia-Pacific Blood and Marrow Transplant Group each have their own unique patient identification system that is compliant with relevant rules for protection of privacy. The Eastern Mediterranean Blood and Marrow Transplantation Group is currently in the process of assigning a Unique Patient Identification Number (UPIN) based on country code, city code and hospital code. In the context of the worldwide network for Blood and Marrow Transplantation, a framework for sharing registry data while avoiding overlap through use of limited identifiable information is being discussed. Although the World Health Organization has stipulated that data collection and data analysis should be considered mandatory components of cell and tissue transplantation programs such as HSCT, competent authorities are challenged to implement solutions that address ethical, legal and privacy considerations.
Data management
Usefulness of an outcome registry is directly related to the scope and quality of the data collected. The scope of the data collected by the outcome registry is framed by the purpose and objectives, but is affected by many other factors. Geographic location and setting of data collection for the target population help to define the scope of a registry. The number of observations necessary to achieve the objectives will affect the size of the registry, as will the complexity of the data elements and outcomes deemed essential to be collected by the registry organizers. The duration of data collection is an important consideration to achieve registry objectives, but must be balanced by the ability to reliably collect the data.
Balancing the costs of registry management with the burden of data collection and the value of the information generated will frame the scope of the registry. Registries should define a core data set of essential data elements and patient outcomes that will address the critical questions anticipated by the purpose and objectives for which it was created. The core data set should be defined by clinical, epidemiological and biostatistical experts; balance the burden of data collection with the value; and be reevaluated periodically to be current with the field or changing objectives of the registry. In HSCT, an internationally accepted core data set has been established through initial collaboration of experts from the two largest outcome registries (Center for International Blood and Marrow Transplantation and EBMT), Challenges and opportunities for HSCT outcome M Aljurf et al working with accreditation bodies. The data contained in the core data set are now recognized internationally as a model for HSCT registries, and the worldwide network for Blood and Marrow Transplantation has endorsed the use of standard data elements contained in this core data set for any program beginning to establish an HSCT registry. Case report forms need to be periodically revised, to make them up-to-date, especially in relation to new diagnostic and prognostic markers as well as treatment modalities. Redundancy in data collection can also be a challenge as different centers report to several international registries. Accuracy, integrity and completeness of data are the most important elements in the quality and value of any registry. Low data quality can be due to inadequate collection of data at individual reporting sites, inattentive abstracting of information from clinical data sources, poor definition and specificity of data elements, inadequate understanding of complex data elements by those providing the data and lack of incentive and collaboration among reporting centers. Comparability of data is essential for interpretation and this in turn, depends on standardization of the methodology and the diagnostic criteria applied. These threats to data quality must be addressed by the outcome registry. Effective quality control using regular internal and external audits and monitoring site visits can help to achieve these foremost goals. Quality and performance improvement can be augmented by continuous updating of the case report forms, advanced survey forms, data collection and follow-up mechanisms. Long-term follow-up of registry participants represents a particular challenge. In a specialty model registry, such as HSCT, recipients are typically not followed long term by the transplant center that performed the procedure. However, the data collected at time points beyond 1 year is difficult for non-HSCT providers to interpret, especially as they are usually not engaged in the purpose and value of the registry. The burden of providing long-term follow-up is substantial for the HSCT centers, even while the unique value of an outcome registry for late effects is readily acknowledged. With growing numbers of HSCT recipients having an interest in longterm complications, and access to the internet, HSCT registries are beginning to explore direct-to-patient communication as a means to maintain long-term follow-up. Cross-training of the data managers to have a broader understanding of the multidisciplinary approach in the HSCT can be very helpful to overcome this challenge. Continuous education and advanced training of the data professionals/registrars at the participating centers in the registry can enhance quality and compliance with reporting standards.
Transplant registries, with effective data management, are intended for creation of a database that would identify and describe the quantity and quality of transplants and outcomes. Registries outcomes encompass time trends in stage, treatment patterns and survival outcomes. Treatment improvement will transpire if survival outcome derived from registries can serve as a guide for the quality of care in the future.
Most data collection for HSCT outcome registries is conducted using electronic applications. Good quality information systems are needed for effective data collection to support the registry. They must be user friendly, cost effective to maintain, reliable with minimal downtime, validated and compatible with standard operating systems. Web-based data entry applications, with robust data validation tools are needed to streamline observational registries, enhance electronic data capturing efforts and to provide tools for centers to receive back and analyze their own data for quality and performance improvement projects and research.
Communication and cultural issues Language barriers among different countries participating in a regional or international registry can be a challenge. There can be several languages, dialects and norms stemming from a historic background of different countries taking part in the registry. There can be enormous cultural, social and economical heterogeneity. Cultural sensitivities can be another challenge, especially when trying to incorporate collection of patient reported information, such as quality of life data. Occasionally, there are limitations in using certain quality of life tools for socio-cultural reasons and conservatism in general. Quality of life forms need to be culturally sensitive and validated, specifically for those regions.
Performance/quality management Outcome registries can be a key component of HSCT centers' quality management/performance improvement programs. The current accreditation bodies for HSCT in the United States and Europe, Foundation for the Accreditation of Cellular Therapy and Joint Accreditation Committee of the International Society of Cellular Therapy Europe and the EBMT, require that HSCT programs collect and use the standard core data set defined by the field to analyze and understand their program quality. 12 Accreditation helps in implementing basic unified standards and uniformity for good clinical practice across the board among all participating centers for accuracy, integrity, reliability and transparency of the registry data. A future objective for HSCT registries is to exploit this synergy of data collection and accreditation to achieve better integration of outcome registry reporting and centres' use of the reported data for their own performance improvement objectives. Outcome registries can also provide a quality context or benchmark for HSCT centers to use when evaluating the performance of their program. Registries can also facilitate research into quality management that informs improvements in transplant practices and individual center outcomes. Different transplant centers use different lab units/ standards, toxicity criteria (Bearman et al., 13 Common Terminology Criteria for Adverse Events and World Health Organization), GVHD definitions (National Institutes of Health, 14 others) and performance status (Karnofsky Performance Status, Eastern Cooperative Oncology Group/Zubrod and so on), to name a few. Poor data quality leads to inconsistency and fragmentation of the data. The registry case report forms and database need to be periodically reviewed by the audit committee and the Principal Investigator/ Working Committee Chairs in order to incorporate the new variables, biomarkers, staging (American Joint Committee on Cancer (AJCC) 7.0 versus 8.0), grading and so on. High-quality registry requires strong methodology and operational excellence. Levels of rigor that enhance validity and usefulness for guiding decisions are research quality (scientific process) and evidence quality (data/findings).
Data utilization and publications
Findings from observational research have led to significant improvement in the field of HSCT and better clinical trial planning. 15 Collaboration and sharing of data for maximum utilization and optimizing patient outcome is the key to an effective registry. [16] [17] [18] Many centers report data to a myriad of overlapping registries and databases. Integration, interfacing and interoperability are the key ingredients for optimum outcomes and use of these registries. Centers submitting data need to have full access to their own center's data in a registry. There is a need to develop harmonized registry forms encompassing existing forms (for example, Minimum Essential Data (MED-A) and Pre-Transplant Essential Data (Pre-TED)) for standardization, uniformity, validity and homogeneity. Strict adherence to well-outlined authorship guidelines needs to be followed and unanimously approved by the participating centers based on number of transplants, contribution and the centre's participation.
An ideal registry will enhance the understanding of transplant outcomes by addressing questions such as transplant results in specific patient groups, analysis of prognostic factors, evaluation of new transplant regimens, comparison of transplant with non-transplant therapy, defining inter-center variability in practice and outcome, characterizing rare late effects and developing innovative analytical approaches. 19, 20 Linking with other epidemiological data can provide insights into the availability and economics of HSCT. Linking clinical data with immunological and genetic information can provide important insights into transplant biology.
HSCT registry can have a significant role in designing the randomized control clinical trials. Registry data can be very helpful in focusing prospective transplantation trials in areas not well studied and understood, especially the role of geographical variations, genetic differences, genotypic and phenotypic variations and biology of disease by providing preliminary data. It can help in developing and improving the use and efficacy of innovative and novel therapeutic strategies. It can also be utilized in the estimation of outcomes and accrual patterns, sample size calculations and implementation plans. Information about the most commonly used supportive care measures can be used to adapt protocols to standard practices and thus, increase their acceptability in the transplant community. Comparison of clinical trials outcomes with observational outcomes can give an insight about generalizability and patient selection practices. Source of stem cells is highly influenced by chance for each patient and on many occasions, it will not be possible to apply prospective randomization to answer some of the important clinical questions. Therefore, well-designed retrospective observational studies, using a registry database, can provide important information that is highly applicable to clinical practice in HSCT [21] [22] [23] and significantly helpful in clinical trials planning. 24 Funding and sustainability Depending on its objectives, an outcome registry may take several years to develop sufficient numbers of subjects to provide meaningful information. Particular strengths of registries, as elaborated above, are to track and report evolving trends in practice, and collect sufficient numbers of patients to identify and report rare events, such as late effects of interventions. Registry operations to collect complete, high-quality data are resource intense. For these and other reasons, outcome registries are generally intended to operate for long periods of time. To be sustainable over this time horizon, particular attention must be given to long-term funding solutions. Consideration of the intended uses of the registry and those who can derive value from registry information should provide guidance to potential funding sources. These may include government agencies, scientific granting organizations, research collaborators, pharmaceutical manufacturers, accreditation bodies, philanthropic organizations and others. Government regulatory agencies, that may have particular interest in a registry to provide information regarding utilization and outcomes of services it supports, may represent a source of funding. In the context of the contract for the US Stem Cell Therapeutic Outcomes Database, the Center for International Blood and Marrow Transplantation derives substantial funding from the Department of Health and Human Services to support its outcome registry operations. Data collected for this effort are also used to indirectly support reporting of cord blood information to the Food and Drug Administration. As an outcome registry develops robust information, it can be a rich source of data for research, and grant funding to support research represents an excellent opportunity. Such funding may come through resource grants to support overall registry function, or through funding for individual research project grant support. Pharmaceutical or device manufacturers may have an interest in registry data to better understand utilization of their products, and short-term projects or long-term reporting may represent a source of compensation for the registry. Outcome registries must remain vigilant for new innovation or collaborative opportunities to use or expand the registry to seize new funding opportunities.
Registries at the beginning of their life cycle will need a plan for growth and development that matches registry size and comprehensiveness with the available resources. Early data collection may be relatively simple and focus on complete collection of the most essential data elements necessary for regulatory, government and accreditation, and quality improvement purposes. This foundation can be used to demonstrate early success on which to build confidence and develop additional funding initiatives, including research.
CONCLUSION
There is a growing acknowledgment of a clear need to have a HSCT database on institutional, national, continental and global levels. The standardization of data quality is essential to ascertain scientific credibility and function of international HSCT registries. It will also enhance registries collaboration and function worldwide. It can then serve as a global data and research tool as well as an instrument for health technology assessment.
